Advertisement
Organisation › Details
Qiagen (Group)
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide. *
Start | 1985-01-01 established | |
Predecessor | Diagen | |
Industry | sample preparation (service) | |
Industry 2 | molecular diagnostics | |
Person | Bernard, Thierry (Qiagen 201502– SVP Molecular Dx business area before bioMérieux Corp VP Commcercial Operations) | |
Person 2 | Sackers, Roland (Qiagen 200408 CFO) | |
Region | Hilden | |
Country | Germany | |
Street | 1 Qiagen Str. | |
City | 40724 Hilden | |
Tel | +49-2103-29-0 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | G: 5,001 to 10,000 (2022-12-31) |
Currency | USD | |
Annual sales | 2,141,518,000 (net sales, consolidated (2022) 2022-12-31) | |
Profit | 423,211,000 (2022-12-31) | |
Cash | 730,669,000 (2022-12-31) | |
* Document for »About Section«: | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Qiagen (Group)
- [1] Evotec SE. (6/3/24). "Press Release: Evotec and Qiagen Enter Software Collaboration for Enhanced Multi-omics Data Insights". Hamburg & Venlo....
- [2] Qiagen N.V.. (1/4/24). "Press Release: Qiagen to Accelerate Investments into Qiagen Digital Insights Bioinformatics Business". Venlo....
- [3] Qiagen N.V.. (9/25/23). "Press Release: Qiagen Enhances QIAwave Portfolio with New Eco-friendlier Nucleic Acid Extraction Kits". Venlo....
- [4] Qiagen N.V.. (9/11/23). "Press Release: Qiagen Launches API to Streamline Access to World-leading Biomedical Data for AI Integration". Venlo & Redwood City, CA....
- [5] Qiagen N.V.. (8/8/23). "Press Release: Qiagen Delivers Ahead of Outlook for Q2 2023 with 9% CER Sales Growth in Non-COVID Products and Updates 2023 Full-year Outlook". Venlo....
- [6] Qiagen N.V.. (8/7/23). "Press Release: Qiagen Receives FDA Approval for Companion Diagnostic to Blueprint Medicines’ Ayvakit (avapritinib) in Gastrointestinal Stromal Tumors". Venlo & Germantown, MD....
- [7] Qiagen N.V.. (7/26/23). "Press Release: Bio-Rad and Qiagen Announce Patent Settlement and Cross-licensing Agreement". Venlo....
- [8] Qiagen N.V.. (6/13/23). "Press Release: Danish National Genome Center Selects Qiagen for Variant Interpretation in Oncology Genome Sequencing". Venlo & Redwood City, CA....
- [9] Qiagen N.V.. (5/15/23). "Press Release: Qiagen Expands Enzyme Offering to Support Individual Life Science Research Labs Worldwide". Berlin....
- [10] Qiagen N.V.. (5/3/23). "Press Release: Qiagen Exceeds Outlook for Q1 2023 with 12% CER Sales Growth in Non-COVID Product Portfolio". Venlo....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top